The Steno hypothesis proposes albuminuria to reflect cytokine family that induces angiogenesis and markedly ina more generalized vascular process which affects the creases endothelial permeability. The aim of the present study glomeruli in the kidneys, the retina and the intima of was to investigate plasma levels of VEGF in a large cohort of type 1 diabetic patients with diabetic nephropathy and in longlarge vessels simultaneously [1] . In diabetic microangiostanding type 1 diabetic patients with persistent normoalbumipathy, the hallmark of endothelial dysfunction is an innuria, and to evaluate VEGF as a predictor of nephropathy crease in permeability and-in proliferative diabetic retiprogression. In vitro studies have shown that VEGF is stimulated normoalbuminuria (115 males, age 43 Ϯ 10 years, diabetes duration 27 Ϯ 9 years). One hundred fifty-five of the proteinuric by hyperglycemia, hypoxia, blood pressure elevation, anpatients were followed for at least 3 years after baseline examigiotensin II and insulin-like growth factor 1 [2] [3] [4] [5] [6] . In nation with yearly GFR measurements.
nopathy-neovascularization. Vascular endothelial growth

animals, injection of human recombinant VEGF in the
Results. Plasma levels of VEGF were significantly increased eyes of non-diabetic monkeys produces many of the vasin patients with nephropathy as compared to the normoalbumicular abnormalities seen in diabetic retinopathy [7] . Fur- before the appearance of retinal changes in diabetic rats ences were found between women with and without nephropa- [8, 9] . In humans, VEGF was found to be elevated in crine hormone. Therefore, the aim of this study was to Conclusions. Our data suggest that VEGF is elevated early investigate plasma levels of VEGF in a large cohort of in the course of diabetic nephropathy in men with type 1 diabetype 1 diabetic patients with diabetic nephropathy and tes mellitus. Baseline albuminuria, arterial blood pressure and male gender was predictors of diabetic nephropathy progresin long-standing type 1 diabetic patients with persistent sion, while plasma VEGF and Hemoglobin A 1c did not contribnormoalbuminuria. The potential role of VEGF as a predictor of progression in diabetic nephropathy was evaluated in all (N ϭ 155) of the above-mentioned pro-teinuric patients followed with yearly glomerular filtration rate (GFR) measurements for at least 3 years. but as results from naturally occurring VEGF and recomwith diabetic nephropathy, diagnosed clinically if followbinant human VEGF 121 showed linear curves parallel to ing criteria were fulfilled: Persistent albuminuria Ͼ300 the standard curve of the Quantikine kit, the kit can be mg/24 h in at least 2 out of 3 consecutive 24-hour urine used to determine relative mass values for natural human collections, presence of diabetic retinopathy and no clini-VEGF isoforms. Samples were assayed in duplicate, and cal or laboratory evidence of kidney or renal tract disease if results of duplicates differed more than 10% from other than diabetic glomerulosclerosis [12, 13] . Of the their mean value, the assay was repeated. The minimum 199 nephropathic patients, 155 patients were followed detectable concentration of VEGF was 22.0 ng/L in our for at least 3 years after the baseline examination with laboratory (approximately the concentration of lowest yearly GFR measurements. standard). A subset of samples was analyzed with and A group of 188 persistently normoalbuminuric (uriwithout activation with hydrochloric acid as described nary albumin excretion rate Յ30 mg/24 h) type 1 diabetic by Anthony et al [16] . Plasma sample (50 L) and 0.6 patients (115 men, 73 women) matched for gender, age mol/L hydrochloric acid (25 L) were mixed, added to and duration of diabetes were recruited from our outpa-100 L of assay buffer and incubated in the microtiter tient clinic and served as controls (Table 1) .
plate for 1 hour. The acid was neutralized with 25 L of All patients had been dependent on insulin from the 0.6 mol/L sodium hydroxide and incubated for a further 1 time of diagnosis and received at least two injections of hour. The assay procedure was then followed as deinsulin daily. The local ethical committee approved the scribed by the manufacturer of the kit. By these analysis experimental design, and all patients gave their informed results calculated by extrapolation of the standard curve consent.
were accepted. Urinary albumin concentration was de-A more detailed description of the subjects studied is termined by ELISA [17] from 24 hour urine collections. given in references [14] and [15] .
Hemoglobin A 1c (HbA 1c ) was determined from venous blood samples by high performance liquid chromatograProcedures phy (DIAMAT Analyzer, BIO-RAD, Richmond, CA, All investigations were performed in the morning after USA). Normal range of HbA 1c in our laboratory is 4.1-6.4%. Serum creatinine concentration was assessed an overnight fast, in an attempt to avoid diurnal varia-
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by a kinetic Jaffe's method. Glomerular filtration rate thy group (69%) as compared with the normoalbuminuric group (10%), P Ͻ 0.001. Data on VEGF are prewas measured after a single intravenous injection of 3.7 MBq 51 Cr-EDTA by determining the radioactivity in vesented in Table 2 . In the patients with nephropathy, a correlation between VEGF and diastolic blood pressure nous blood samples taken 180, 200, 220 and 240 minutes after the injection [18] and the results were standardized (r ϭ 0.15, P ϭ 0.03) was found, whereas no correlation between VEGF and blood pressure was present in the for 1.73 m 2 body surface area. Decline in GFR was calculated for all patients with yearly GFR measurements normoalbuminuric patients. Univariate analysis revealed no correlations between level of VEGF and age, HbA 1c , and a minimum of 3 years follow up. A linear regression analysis was performed for each patient, and the slope urinary albumin excretion rate, or serum creatinine in either group. Plasma levels of VEGF was significantly was used to determine the rate of decline in GFR. Arterial blood pressure was measured with a Hawksley random increased in patients with nephropathy as compared to the normoalbuminuric group, P Ͻ 0.001. This difference zero sphygmomanometer (Hawksley & Sons Ltd, Lancing, Sussex, UK) and appropriate cuff size. The measurewas ascribed to elevated VEGF levels in men. We found no difference in women with and without nephropathy, ments were performed twice, on the right arm, after at least 10 minutes rest in the supine position and averaged.
NS. No difference in plasma VEGF was observed between patients receiving antihypertensive treatment at the time Diastolic blood pressure was recorded at the disappearance of Korotkoff sounds (phase V). Coronary heart of investigation and patients who were not taking blood pressure lowering agents neither in the nephropathic nor disease was diagnosed based on electrocardiogram and a World Health Organization questionnaire [15] .
in the normoalbuminuric group (data not shown). Nor were plasma VEGF significantly different in patients on Retinopathy was assessed by fundus photography after pupillary dilatation and graded: nil, simplex or pro-ACE inhibition treatment, NS. When the nephropathic and normoalbuminuric groups were dichotomized acliferative diabetic retinopathy.
cording to presence of coronary heart disease, no differStatistical analysis ence in VEGF levels were revealed between patients with or without coronary heart disease, NS. Plasma VEGF, urinary albumin excretion rate and
The group of patients with proteinuria and GFR above serum creatinine were non-normally distributed and valthe median had a mean GFR of 102 Ϯ 19 mL/min/1.73 ues are given as medians (range), and logarithmically values of log(albuminuria), arterial blood pressure and a multiple linear regression analysis was performed with male gender, while HbA 1c and log(plasma VEGF) did log(VEGF) as dependent variable and backwards selecnot act as predictors. When performing a multiple linear tion including all variables with P Ͻ 0.10 in univariate regression analysis with rate of decline in GFR as depenanalysis. Linear regression analysis was used for calculatdent variable, including all variables with P Ͻ 0.10 in ing rate of decline in GFR for the individual patient.
univariate analysis, only log (albuminuria) was included Multiple regression analysis was performed with rate of in the model, r ϭ 0.32. Plasma VEGF was below the decline in GFR as dependent variable and backwards detection limit (22.0 ng/L) in 60 patients with nephropaselection including all variables with P Ͻ 0.10 in univarithy (30%) and 93 patients with normoalbuminuria ate analysis. A P-value Ͻ 0.05 (two-tailed) was consid-(50%), P Ͻ 0.001. ered statistically significant. All calculations were perIn the nephropathy group plasma levels of VEGF did formed with a commercially available statistics program, not differ significantly between patients with simplex SPSS 8.0 (SPSS Inc., Chicago, IL, USA).
or proliferative retinopathy, P ϭ 0.10. No difference in plasma VEGF was seen in normoalbuminuric patients RESULTS with nil, simplex or proliferative retinopathy, NS. There As shown in Table 1 , patients with diabetic nephropawas no significant difference in the proportion of patients thy had elevated HbA 1c , serum creatinine and blood preswith plasma VEGF below the detection limit according sure, as compared with the normoalbuminuric patients, to retinopathy in either group, NS. Plasma VEGF did not P Ͻ 0.001. Twenty-four percent of the nephropathic padiffer between patients with or without coronary heart tients were spontaneously normotensive. The prevalence disease in either group, NS (data not shown). Acidification and neutralization of samples before analysis increased of proliferative retinopathy was higher in the nephropa- the VEGF values for all groups, Table 3 . The samples nant women, while a radioimmunoassay could. Following an acidification/neutralization step, VEGF could be used in this subanalysis were chosen so that the baseline detected at the same level with both assays. We have VEGF levels were comparable for normoalbuminuric shown that acid treatment also increased the measurable and nephropathic men and women, respectively. The concentration of VEGF in plasma from diabetic patients, increases in VEGF were similar in normoalbuminuric supporting the existence of circulating VEGF binding and nephropathic patients and in men and women.
proteins as suggested by Anthony et al [16] . The increase seemed to be similar in men and women and in normoal-DISCUSSION buminuric and nephropathic patients. The fact that Our study revealed that plasma VEGF was elevated VEGF may exist as various alternatively splice variants, in type 1 diabetic patients with diabetic nephropathy as in partially degraded forms and in complex with binding compared with normoalbuminuric type 1 diabetic paproteins, complicates the evaluation of VEGF in plasma tients. This difference in VEGF levels was ascribed to and serum. Due to the extremely low concentrations in the difference in men. We detected no difference in which VEGF molecular species are found in biological plasma VEGF when the patients with nephropathy were fluids, the current methodology is restricted to methods divided by the median of GFR, suggesting that elevation measuring immunoreactivity. The assay we used applied of plasma VEGF is an early phenomenon in the course of a monoclonal capture antibody directed against a dodiabetic kidney disease. We found a positive correlation main common for all VEGF variants and polyclonal debetween baseline values of albuminuria, arterial blood tecting antibodies. The assay therefore did not discrimipressure, male gender and rate of decline in GFR in the nate between the different molecular forms of VEGF. patients with diabetic nephropathy. HbA 1c and plasma
Whether the circulating VEGF immunoreactivity is bio-VEGF did not act as risk factors for decline in kidney logically active is not known and will be very difficult to function. Baseline albuminuria was the only predictor show due to the low concentrations. The highest concenof progression in diabetic kidney disease when evaluated trations observed in our study was about 400 ng/L, which, in a multiple linear regression analysis.
if it were native VEGF 165 , might stimulate human umbiliAnthony et al [16] have shown that the ELISA assay cal vein endothelial cell proliferation under defined confrom R & D Systems Inc., which is the assay we have ditions in vitro [19] . If active, the high levels found may therefore have physiological relevance. used, was unable to detect VEGF in serum from preg-
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We have confirmed and extended previous studies on the observed large inter-individual variability in plasma levels of VEGF in our study, an association which could diabetic kidney disease and circulating levels of VEGF [20, 21] . Aziz et al reported elevated levels of VEGF in not be evaluated in all patients because kidney biopsies were not available. a mixed population of 76 type 1 and type 2 diabetic patients with and without microvascular complications as A previous study in humans by Aiello et al [10] have reported elevated levels of VEGF in vitreous fluid in compared to 28 age-matched controls [20] . Furthermore, they found a weak correlation (r ϭ 0.27, P Ͻ 0.05) beactive proliferative retinopathy as compared with quiescent proliferative diabetic retinopathy and non-proliferatween the level of albuminuria and serum VEGF. In accordance, Wasada et al [21] , found a tendency towards tive retinopathy. The elevated levels of VEGF declined after successful laser photocoagulation. The absence of increasing levels of VEGF with increasing levels of albuminuria in 110 type 2 diabetic patients, of whom 31 elevated levels of VEGF in our patients with proliferative diabetic retinopathy could be attributed to the fact patients were macroalbuminuric and 42 patients had microalbuminuria. Plasma VEGF was higher in the microthat nearly all of our patients with proliferative diabetic retinopathy had previously undergone laser treatment, and macroalbuminuric groups compared with the normoalbuminuric patients (P ϭ 0.03). In a recent study, and consequently they were not in a state of active proliferative diabetic retinopathy. Furthermore, elevated VEGF urinary VEGF levels were significantly correlated to the degree of proteinuria (r ϭ 0.297) in patients with diabetes levels in the vitreous fluid in the eyes of patients with proliferative diabetic retinopathy has been reported to (abstract; Cha et al, J Am Soc Nephrol 10:A3428, 1999). In the present study, we did not measure urinary levels be produced locally by the ischemic retina, whereas circulating VEGF was not elevated [28] . A role for VEGF in of VEGF.
The difference in VEGF levels between the nephrothe pathogenesis of diabetic retinopathy is possible, since VEGF might act predominately as a paracrine hormone. pathic and the normoalbuminuric patients in our study was ascribed to a difference in men. Since VEGF has
The decline in GFR in diabetic nephropathy is highly variable, ranging from 2 to 20 mL/min/year [29] [30] [31] . This been shown to be elevated and positively correlated to serum progesterone in early pregnancy [22] , one can variability can partly be explained by so called progression promoters, i.e., risk factors for loosing filtration suggest that the menstruation cycle could be a confounder, and thereby mask the possible difference in power. Evaluation of progression promoters can take place at the start of the study or during the course of the VEGF levels in female patients. In addition, atherosclerosis and neuropathy have been suggested to increase study. Baseline progression promoters were evaluated in the Captopril Collaborative study including 409 type 1 circulating VEGF [23, 24] , and thereby be possible confounders. However, the presence of coronary heart disdiabetic patients with diabetic nephropathy, median follow-up time of three years. A number of clinical and ease is unlikely to confound our results, since VEGF was not associated with that condition in our study.
laboratory risk factors that predict doubling of serum creatinine was found, including elevated mean arterial Because no difference in plasma VEGF was seen between nephropathic patients with preserved or reduced blood pressure, high blood glucose, increased serum creatinine, enhanced proteinuria and presence of edema GFR, the elevated VEGF cannot be explained by deterioration in kidney function. Our data suggest that the [32] . In our study, baseline albuminuria, arterial blood pressure, and male gender were found to predict the rate elevation of VEGF occurs early in the course of diabetic kidney disease. Similarly, in a biopsy study of non-diaof decline in GFR, whereas only albuminuria was an independent predictor of progression in kidney disease. betic human glomerulonephritis it was shown that VEGF is elevated early in the course of this disease, and that
We could not identify plasma VEGF at baseline as a progression promoter in diabetic nephropathy in type 1 VEGF activity may promote protein leakage from glomerular capillaries [25] . In another biopsy study of mixed diabetic patients. Progression promoters during the course of diabetic kidney disease were evaluated by Rossing glomerular diseases including diabetic nephropathy, glomeruli with well-preserved architecture had a strong [33] , and may be listed as follows: arterial hypertension, albuminuria, glycemic control, dyslipidemia, smoking, VEGF protein expression, whereas in sclerotic areas, the VEGF-expressing cells were markedly decreased [26] .
and angiotensin-converting enzyme insertion deletion polymorphism. Damaged cells have the potential for releasing large amounts of stored VEGF, which may contribute to the In summary, we found elevated levels of VEGF early in the course of diabetic nephropathy in men with type increased glomerular permeability seen in active glomerular diseases [26] . Both these studies found elevated local 1 diabetes mellitus. Baseline albuminuria, arterial blood pressure and male gender was found to be predictors of levels of VEGF early in the disease process. Furthermore, Grö ne et al [27] found an increased expression of progression in diabetic nephropathy, while VEGF and HbA 1c did not contribute. The importance of VEGF VEGF mRNA in viable podocytes from diabetic patients, whereas a reduced or absent expression was seen in the initiation of diabetic nephropathy remains to be established. in sclerotic glomeruli. This might contribute to explain
